1
|
Otsu Y, Darcq E, Pietrajtis K, Mátyás F, Schwartz E, Bessaih T, Abi Gerges S, Rousseau CV, Grand T, Dieudonné S, Paoletti P, Acsády L, Agulhon C, Kieffer BL, Diana MA. Control of aversion by glycine-gated GluN1/GluN3A NMDA receptors in the adult medial habenula. Science 2020; 366:250-254. [PMID: 31601771 DOI: 10.1126/science.aax1522] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 09/17/2019] [Indexed: 01/05/2023]
Abstract
The unconventional N-methyl-d-aspartate (NMDA) receptor subunits GluN3A and GluN3B can, when associated with the other glycine-binding subunit GluN1, generate excitatory conductances purely activated by glycine. However, functional GluN1/GluN3 receptors have not been identified in native adult tissues. We discovered that GluN1/GluN3A receptors are operational in neurons of the mouse adult medial habenula (MHb), an epithalamic area controlling aversive physiological states. In the absence of glycinergic neuronal specializations in the MHb, glial cells tuned neuronal activity via GluN1/GluN3A receptors. Reducing GluN1/GluN3A receptor levels in the MHb prevented place-aversion conditioning. Our study extends the physiological and behavioral implications of glycine by demonstrating its control of negatively valued emotional associations via excitatory glycinergic NMDA receptors.
Collapse
Affiliation(s)
- Y Otsu
- Institut de Biologie de l'École Normale Supérieure (IBENS), INSERM U1024, CNRS UMR8197, École Normale Supérieure, Université PSL, 75005 Paris, France
| | - E Darcq
- Department of Psychiatry, School of Medicine, Douglas Hospital Research Center, McGill University, Montreal, QC H4H 1R3, Canada
| | - K Pietrajtis
- Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), 75005 Paris, France
| | - F Mátyás
- Laboratory of Thalamus Research, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary.,Research Centre for Natural Sciences Institute of Cognitive Neuroscience and Psychology, 1117 Budapest, Hungary.,Department of Anatomy and Histology, University of Veterinary Medicine, 1078 Budapest, Hungary
| | - E Schwartz
- Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), 75005 Paris, France
| | - T Bessaih
- Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), 75005 Paris, France
| | - S Abi Gerges
- Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), 75005 Paris, France
| | - C V Rousseau
- Institut de Biologie de l'École Normale Supérieure (IBENS), INSERM U1024, CNRS UMR8197, École Normale Supérieure, Université PSL, 75005 Paris, France
| | - T Grand
- Institut de Biologie de l'École Normale Supérieure (IBENS), INSERM U1024, CNRS UMR8197, École Normale Supérieure, Université PSL, 75005 Paris, France
| | - S Dieudonné
- Institut de Biologie de l'École Normale Supérieure (IBENS), INSERM U1024, CNRS UMR8197, École Normale Supérieure, Université PSL, 75005 Paris, France
| | - P Paoletti
- Institut de Biologie de l'École Normale Supérieure (IBENS), INSERM U1024, CNRS UMR8197, École Normale Supérieure, Université PSL, 75005 Paris, France
| | - L Acsády
- Laboratory of Thalamus Research, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary
| | - C Agulhon
- Integrative Neuroscience and Cognition Center, CNRS UMR8002, Glia-Glia and Glia-Neuron Interactions Group, Paris Descartes University, 75006 Paris, France
| | - B L Kieffer
- Department of Psychiatry, School of Medicine, Douglas Hospital Research Center, McGill University, Montreal, QC H4H 1R3, Canada
| | - M A Diana
- Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), 75005 Paris, France.
| |
Collapse
|
2
|
Haller J, Mátyás F, Soproni K, Varga B, Barsy B, Németh B, Mikics E, Freund TF, Hájos N. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007; 25:2445-56. [PMID: 17445240 PMCID: PMC1890583 DOI: 10.1111/j.1460-9568.2007.05476.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cannabinoid ligands show therapeutic potential in a variety of disorders including anxiety. However, the anxiety-related effects of cannabinoids remain controversial as agonists show opposite effects in mice and rats. Here we compared the effects of the cannabinoid agonist WIN-55,212 and the CB1 antagonist AM-251 in CD1 mice and Wistar rats. Special attention was paid to antagonist–agonist interactions, which had not yet been studied in rats. In mice, WIN-55,212 decreased whereas AM-251 increased anxiety. The antagonist abolished the effects of the agonist. In contrast, WIN-55,212 increased anxiety in rats. Surprisingly, the antagonist potentiated this effect. Cannabinoids affect both GABAergic and glutamatergic functions, which play opposite roles in anxiety. We hypothesized that discrepant findings resulted from species differences in the relative responsiveness of the two transmitter systems to cannabinoids. We investigated this hypothesis by studying the effects of WIN-55,212 on evoked hippocampal inhibitory and excitatory postsynaptic currents (IPSCs and EPSCs). IPSCs were one order of magnitude more sensitive to WIN-55,212 in mice than in rats. In mice, IPSCs were more sensitive than EPSCs to WIN-55,212. This is the first study showing that the relative cannabinoid sensitivity of GABA and glutamate neurotransmission is species-dependent. Based on behavioural and electrophysiological findings, we hypothesize that WIN-55,212 reduced anxiety in mice by affecting GABA neurotransmission whereas it increased anxiety in rats via glutamatergic mechanisms. In rats, AM-251 potentiated this anxiogenic effect by inhibiting the anxiolytic GABAergic mechanism. We suggest that the anxiety-related effects of cannabinoids depend on the relative cannabinoid responsiveness of GABAergic and glutamatergic neurotransmission.
Collapse
Affiliation(s)
- J Haller
- Institute of Experimental Medicine, Department of Behavioral Neurobiology, 1450 Budapest, PO Box 67, Hungary.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Mátyás F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2005; 137:337-61. [PMID: 16289348 DOI: 10.1016/j.neuroscience.2005.09.005] [Citation(s) in RCA: 147] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2005] [Revised: 09/08/2005] [Accepted: 09/09/2005] [Indexed: 11/29/2022]
Abstract
Endocannabinoids, acting via type 1 cannabinoid receptors (CB1), are known to be involved in short-term synaptic plasticity via retrograde signaling. Strong depolarization of the postsynaptic neurons is followed by the endocannabinoid-mediated activation of presynaptic CB1 receptors, which suppresses GABA and/or glutamate release. This phenomenon is termed depolarization-induced suppression of inhibition (DSI) or excitation (DSE), respectively. Although both phenomena have been reported to be present in the basal ganglia, the anatomical substrate for these actions has not been clearly identified. Here we investigate the high-resolution subcellular localization of CB1 receptors in the nucleus accumbens, striatum, globus pallidus and substantia nigra, as well as in the internal capsule, where the striato-nigral and pallido-nigral pathways are located. In all examined nuclei of the basal ganglia, we found that CB1 receptors were located on the membrane of axon terminals and preterminal axons. Electron microscopic examination revealed that the majority of these axon terminals were GABAergic, giving rise to mostly symmetrical synapses. Interestingly, preterminal axons showed far more intense staining for CB1, especially in the globus pallidus and substantia nigra, whereas their terminals were only faintly stained. Non-varicose, thin unmyelinated fibers in the internal capsule also showed strong CB1-labeling, and were embedded in bundles of myelinated CB1-negative axons. The majority of CB1 receptors labeled by immunogold particles were located in the axonal plasma membrane (92.3%), apparently capable of signaling cannabinoid actions. CB1 receptors in this location cannot directly modulate transmitter release, because the release sites are several hundred micrometers away. Interestingly, both the CB1 agonist, WIN55,212-2, as well as its antagonist, AM251, were able to block action potential generation, but via a CB1 independent mechanism, since the effects remained intact in CB1 knockout animals. Thus, our electrophysiological data suggest that these receptors are unable to influence action potential propagation, thus they may not be functional at these sites, but are likely being transported to the terminal fields. The present data are consistent with a role of endocannabinoids in the control of GABA, but not glutamate, release in the basal ganglia via presynaptic CB1 receptors, but also call the attention to possible non-CB1-mediated effects of widely used cannabinoid ligands on action potential generation.
Collapse
Affiliation(s)
- F Mátyás
- Institute of Experimental Medicine, Hungarian Academy of Sciences, PO Box 67, Budapest H-1450, Hungary
| | | | | | | | | | | |
Collapse
|